HCM:NSD-HUTCHMED DRC (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 15.12

Change

+0.12 (+0.80)%

Market Cap

USD 2.63B

Volume

0.04M

Analyst Target

USD 35.28
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
UTHR United Therapeutics Corporatio..

+4.10 (+1.39%)

USD 13.14B
NBIX Neurocrine Biosciences Inc

+0.07 (+0.06%)

USD 9.54B
VTRS Viatris Inc

-0.06 (-0.69%)

USD 9.00B
LNTH Lantheus Holdings Inc

-0.76 (-0.70%)

USD 7.11B
ALKS Alkermes Plc

-0.38 (-1.20%)

USD 4.74B
ALVO Alvotech

+0.11 (+1.34%)

USD 2.57B
SUPN Supernus Pharmaceuticals Inc

-0.45 (-1.37%)

USD 1.80B
ANIP ANI Pharmaceuticals Inc

-0.39 (-0.53%)

USD 1.51B
INDV Indivior PLC Ordinary Shares

-0.08 (-0.67%)

USD 1.44B
BCRX BioCryst Pharmaceuticals Inc

+2.10 (+23.52%)

USD 1.43B

ETFs Containing HCM

AXJV 0.00 % 0.35 %

N/A

N/A
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

-0.32 (0%)

USD 7.65M
IPOS Renaissance International.. 0.00 % 0.80 %

+0.04 (+0%)

N/A
CHNA 0.00 % 0.62 %

N/A

N/A
CHNA 0.00 % 0.79 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.93% 67% D+ 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.93% 67% D+ 78% C+
Trailing 12 Months  
Capital Gain -23.71% 57% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.71% 57% F 36% F
Trailing 5 Years  
Capital Gain -29.15% 57% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.15% 57% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain -2.62% 38% F 35% F
Dividend Return -2.62% 38% F 32% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 41.61% 72% C 43% F
Risk Adjusted Return -6.30% 35% F 33% F
Market Capitalization 2.63B 93% A 83% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.